Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): Mechanisms of action

Transfusion Science

Volumn 19, Issue 3, 1998, Pages 289-294

  Lazarus, Alan H ^a,b,c   Freedman, John ^a,b,c   Semple, John W ^b,c  

^a CANADIAN BLOOD SERVICES   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c Toronto Platelet Immunobiology Group   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; RHESUS D ANTIBODY;

DRUG EFFECT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; RETICULOENDOTHELIAL SYSTEM; REVIEW;

EID: 0346390594     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(98)00043-5     Document Type: Article

References (34)

1. Imbach P, Barandun S, d'Apuzzo V, et al.: High dose intravenous gamma globulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-1230.
2. Salama A, Mueller-Eckhardt C, Kiefel V: Effect of intravenous immunoglobulin in immune thrombocytopenia: Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells? Lancet 1983; 2:193-195.
3. 0(D)). Blut 1984; 49:29-35.
4. Fehr J, Hofmann V, Kappeler U, et al.: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254-1258.
5. Bussel JB, Kimberly RP, Inman RD, et al.: Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983; 62:480.
6. Uchida T, Yui T, Umezu H: Prolongation of platelet survival in idiopathic thrombocytopenic purpura by high-dose gamma globulin. Thromb Haemost 1984; 51:65-66.
7. Macintyre EA, Linch DC, Macey MG, et al.: Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. Br J Haematol 1985; 60:387-388.
8. Newland AC, Macey MG: Immune thrombocytopenia and Fc receptor-mediated phagocyte function. Ann Hematol 1994; 69:61-67.
9. Tovo PA, Miniero R, Fiandino G, et al.: Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr 1984; 105:676-677.
10. Burdach SE, Evers KG, Geursen RG: Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: Comparative efficacy of 7S and 5 S preparations. J Pediatr 1986; 109:770-775.
11. Kurlander RJ, Hall J: Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986; 77:2010-2018.
12. Bussel JB, Graziano JN, Kimberly RP: Anti-D Ig for treatment of immune thrombocytopenic purpura (Letter). Blood 1991; 78:2157-2158.
13. Oksenhendler E, Bierling P, Brossard Y, et al.: Anti-Rh immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura. Blood 1988; 71:1499-1502.
14. Cardo LJ, Strack M, Williams J, et al.: Anti-D for the treatment of splenectomized patients with immune thrombocytopenic purpura (Letter). Blood 1991; 78:2786-2787.
15. Bussel JB, Graziano JN, Kimberly RP, et al.: Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect. Blood 1991; 77:1884-1893.
16. 0(D) in adult patients with chronic autoimmune thrombocytopenia. Am J Hematol 1986; 22:241-250.
17. Scaradavou A, Woo B, Woloski BMR, et al.: Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood 1997; 89:2689-2700.
18. Godeau B, Oksenhendler E, Brossard Y, et al.: Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D. Transfusion 1996; 36:328-330.
19. Moise KJ, Cano LE, Sala DJ: Resolution of severe thrombocytopenia in a pregnant patient with rhesus-negative blood with autoimmune thrombocytopenic purpura after intravenous rhesus immune globulin. Am J Obstet Gynecol 1990; 162:1237-1238.
20. Berchtold P, Dale GL, Tani P, et al.: Inhibition of autoantibody binding to platelet glycoprotein IIb/IIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989; 74:2414-2422.
21. Boughton BJ, Cooke RM, Smith NA et al.: Autoimmune thrombocytopenia: anti-glycoprotein IIb/IIa auto antibodies are reduced after human anti-D immunoglobulin treatment. Autoimmit 1994; 18:141-144.
22. Atlas E, Freedman J, Blanchette V, et al.: Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. Blood 1993; 81:538-542.
23. Delfraissy JF, Tchernia G, Laurian Y, et al.: Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol 1985; 60:315-322.
24. Dammacco F, Iodice G, Campobasso N, et al.: Treatment of adult patients with intravenous immunoglobulin: Effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro. Br J Haematol 1986; 62:125-135.
25. Macey MG, Newland AC: CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Haematol 1990; 76:513-520.
26. Tsubakio T, Kurata Y, Katagiri S, et al.: Alteration of T cell subsets and immunoglobulin synthesis in vitro during high-dose γ-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 1983; 53:697-702.
27. Chiller JM, Habicht GS, Weigle WO: Cellular sites of immunological unresponsiveness. Proc Natl Acad Sci USA 1970; 65:551-555.
28. Aukrust P, Frøland SS, Liabakk NB, et al.: Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-2143.
29. Andersson JP, Andersson UG: Human intravenous immunoglobulin modulates monokine production in vitro. Immunol 1990; 71:372-376.
30. Andersson UG, Björk L, Skansén-Saphir U, et al.: Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunol 1993; 79:211-216.
31. Modiano JF, Amran D, Lack G, et al.: Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobulin. Clin Immunol Immunopath 1997; 83:77-85.
32. Vuist WMJ, Van Schaik IN, Van Lint M, et al.: The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Invest 1997; 17:301-310.
33. Basta M, Langlois PF, Marques M, et al.: High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989; 74:326-333.
34. Kekow J, Reinhold D, Pap T., Ansorge S: Intravenous immunoglobulins and transforming growth factor β. Lancet 1998; 351:184-185.